Table 2.

List of c(RGD) multimeric radioligands α_vβ₃-integrin cell and tumor models tested.

#	Name	Cell & Tumor Model	Ref.	Figure
1	[18F]FBOA-Dpr-HEG-c(RGDfE)	M21 Human melanoma U87MG human glioblastoma	[22,33]	Figure 2
2	[18F]FBOA-Dpr-K(HEG-c(RGDfE))2
3	[18F]FBOA-Dpr-K{K[HEG-(c(RGDfE)]2}2
4	[18F]FB-E[c(RGDyK)]2	HBCECs human brain capillary endothelial cells, U87MG	[34,35]	Figure 3
5	[18F]FP-E[c(RGDyK)]2 18F-FP-RGD2	U87MG
6	[18F]AlF-NOTA-E[c(RGDyK)]2 [18F]AlF-NOTA-RGD2	U87MG	[35,46]
7	[18F]FB-PEG3-E[c(RGDyK)]2 [18F]FB-PRGD2	U87MG	[36,37]
8	[18F]FP-PEG3-E[c(RGDyK)]2 [18F]FP-PRGD2	HCT116 human colon cancer, U87MG	[27,39,72,73,74]
9	[68Ga]Ga-NOTA-PEG3-E[c(RGDyK)]2	U87MG	[38,39]
10	[18F]AlF-NOTA-PEG3-E[c(RGDyK)]2 [18F]Alfatide I	U87MG, A549 adenocarcinomic human alveolar basal epithelial cells, PC-3 prostate cancer, LLC Lewis Lung Carcinoma	[38,39,40,41,76,77]
11	[18F]FP-PEG4-E[c(RGDfK)]2 [18F]FP-PRGD2	U87MG, MDA-MB-435	[45]	Figure 4
12	[68Ga]Ga-NOTA-PEG4-E[c(RGDfK)]2	U87MG	[78]
13	[18F]AlF-NOTA-PEG4-E[c(RGDfK)]2	U87MG	[46]
14	[18F]AlF-NOTA-E[PEG4-c(RGDfK)]2, [18F]Alfatide II	U87MG, MDA-MB-435 human breast cancer	[43,44,46,52,53,54]
15	[68Ga]Ga-NOTA-E[PEG4-c(RGDfK)]2 [68Ga]Ga-NOTA-PRGD2,	-	[51,79]
16	[18F]FP-PEG4-E[PEG4-c(RGDfK)]2 [18F]FP-PPRGD2	U87MG, MDA-MB-435	[45]
17	[18F]FP-PEG2-β-E[c(RGDyK)]2	A549, PC-3	[47]	Figure 5
18	[18F]FP-SAA-E[c(RGDyK)2	U87MG	[48]	Figure 6
19	[18F]FB-SAA-E[c(RGDyK)2
20	NOTA-E[c(RGDyK)]2	-	[49]	Figure 7
21	[68Ga]Ga-NOTA-E[c(RGDyK)]2
22	[68Ga]Ga-NOTA-Y-c(RGDyK)] (Y =2-(4-anilinyl-methyl)-4-(3-oxopropyl)thiazol-5(4H)-one)
23	[64Cu]Cu-DOTA-E[c(RGDfK)]2	U87MG, MDA-MB-435	[55,56]	Figure 8
24	[68Ga]Ga-DOTA-E[c(RGDfK)]2	B16-F10-luc melanoma tumors, SK-RC-52, FaDu	[61,70]
25	[64Cu]Cu-DOTA-E[c(RGDyK)]2	MDA-MB-435	[55]
26	[64Cu]Cu-DOTA-E{E[c(RGDfK)]2}2	U87MG	[56,58]
27	[64Cu]Cu-DOTA-E{E[c(RGDyK)]2}2	U87MG, c-neu onco-mice	[30]
28	[64Cu]Cu-DOTA-E(E{E[c(RGDfK)]2}2)2	U87MG, c-neu onco-mice	[30]
29	[64Cu]Cu-NOTA-PEG4-E[(PEG2-Tz-c(RGDfK)]2	HUVEC human umbilical vein endothelial cells	[57]	Figure 9
30	FITC-PEG4-E[PEG2-Tz-c(RGDfK)]2
31	[64Cu]Cu-DOTA-PEG4-E[PEG4-c(RGDfK)]2	U87MG	[58]
32	[64Cu]Cu-DOTA-G3-E[G3-c(RGDfK)]2
33	[64Cu]Cu-AmBaSar-E[c(RGDyK)]2	U87MG	[59,60]	Figure 10
34	[64Cu]Cu-AmBaBaSar-c(RGDyK)2
35	[68Ga]Ga-NOTA-E[PEG4-c(RGDfK)]2	U87MG: MDA-MB-435	[62]	Figure 11
36	[68Ga]Ga-NOTA-E[G3-c(RGDfK)]2	U87MG, MDA-MB-435, HT1080 fibrosarcoma	[62,64]
37	[68Ga]Ga-NOTA-E[G3-c(CNGRC)]2	HT1080 fibrosarcoma	[64]
38	[68Ga]Ga-NOTA-E[c(RGDyK)]2	U87MG	[66]
39	[68Ga]Ga-NOTA-E{E[c(RGDyK)]2}2
40	[68Ga]Ga-NODAGA-E[c(RGDyK)]2	U87MG, H727 human neuroendocrine	[67]
41	[64Cu]Cu-NODAGA-E[c(RGDyK)]2
42	[68Ga]Ga-FSC-[E-c(RGDfK)]3	M21 human melanoma, SK-RC-52 (human renal cell carcinoma), FaDu (human squamous cell carcinoma)	[68,70]	Figure 12
43	[68Ga]Ga-FSC-(CH2)-Tz-c(RGDfK)	U87MG, M21 human melanoma	[23]
44	[68Ga]Ga-FSC-[(CH2)-Tz-c(RGDfK)]2
45	[68Ga]Ga-FSC-[(CH2)-Tz-c(RGDfK)]3
46	[68Ga]Ga-TRAP-PEG4-c(RGDfK)3	M21 human melanoma, SK-RC-52, FaDu	[69,70]	Figure 13
47	[68Ga]Ga-THP-c(RGDfK)3	SK-RC-52, FaDu	[70]